Tiaa Fsb trimmed its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 2.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,128 shares of the medical instruments supplier’s stock after selling 801 shares during the period. Tiaa Fsb’s holdings in Becton Dickinson and were worth $7,114,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. InterOcean Capital LLC bought a new stake in shares of Becton Dickinson and in the first quarter worth $204,000. Private Advisor Group LLC increased its holdings in Becton Dickinson and by 6.5% during the first quarter. Private Advisor Group LLC now owns 8,792 shares of the medical instruments supplier’s stock worth $2,190,000 after buying an additional 537 shares during the last quarter. Wealthfront Advisers LLC increased its holdings in Becton Dickinson and by 53.1% during the first quarter. Wealthfront Advisers LLC now owns 7,642 shares of the medical instruments supplier’s stock worth $1,908,000 after buying an additional 2,650 shares during the last quarter. Aureus Asset Management LLC increased its holdings in Becton Dickinson and by 9.6% during the first quarter. Aureus Asset Management LLC now owns 3,985 shares of the medical instruments supplier’s stock worth $995,000 after buying an additional 350 shares during the last quarter. Finally, Neuburgh Advisers LLC increased its holdings in shares of Becton Dickinson and by 3.2% in the first quarter. Neuburgh Advisers LLC now owns 15,920 shares of the medical instruments supplier’s stock valued at $3,976,000 after purchasing an additional 496 shares during the last quarter. Institutional investors own 84.21% of the company’s stock.

In related news, Director Claire Fraser sold 1,429 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Vincent A. Forlenza sold 11,532 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the sale, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. Insiders have sold 37,249 shares of company stock valued at $9,616,803 in the last ninety days. 0.12% of the stock is currently owned by company insiders.

Shares of BDX stock traded up $2.38 on Wednesday, hitting $246.86. The company’s stock had a trading volume of 71,352 shares, compared to its average volume of 1,166,997. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09. The stock’s 50 day moving average is $253.78 and its 200-day moving average is $245.73. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $264.74. The company has a market capitalization of $68.33 billion, a PE ratio of 22.42, a PEG ratio of 1.62 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period in the prior year, the company posted $2.91 earnings per share. Becton Dickinson and’s revenue was up 1.7% compared to the same quarter last year. On average, research analysts forecast that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 6th. This represents a $3.08 annualized dividend and a yield of 1.25%. Becton Dickinson and’s dividend payout ratio is 27.97%.

Several equities analysts have commented on BDX shares. Piper Jaffray Companies decreased their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Wells Fargo & Co upped their price target on shares of Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Raymond James upped their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Finally, Morgan Stanley upped their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $266.55.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Elliott Wave Theory

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.